| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(98)03339-X |
| P698 | PubMed publication ID | 9989717 |
| P50 | author | Jochen Hampe | Q30348904 |
| P2093 | author name string | H Lochs | |
| S Schreiber | |||
| S Nikolaus | |||
| A Raedler | |||
| I Koop | |||
| B Groessner | |||
| J Hämling | |||
| P2860 | cites work | Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease | Q73107122 |
| Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein | Q73502940 | ||
| On the Kolmogorov-Smirnov Test for Normality with Mean and Variance Unknown | Q73665024 | ||
| Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis | Q28239197 | ||
| Inflammatory bowel disease | Q28275666 | ||
| Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease | Q34392301 | ||
| Microscopic activity in ulcerative colitis: what does it mean? | Q34393414 | ||
| Predictors of acute relapse of Crohn's disease. A laboratory and clinical study | Q43770141 | ||
| Disease activity courses in a regional cohort of Crohn's disease patients. | Q50593816 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine | Q68350435 | ||
| A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease | Q69641067 | ||
| Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease | Q70489716 | ||
| Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) | Q70542302 | ||
| Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group | Q70824726 | ||
| Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease | Q72189511 | ||
| Intestinal permeability and the prediction of relapse in Crohn's disease | Q72220492 | ||
| P433 | issue | 9151 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | interleukins | Q194908 |
| Crohn's disease | Q1472 | ||
| TNF | Q18032037 | ||
| P304 | page(s) | 459-461 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease | |
| P478 | volume | 353 |
| Q40600502 | 99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease |
| Q45264282 | A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease |
| Q35594920 | Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease |
| Q38243723 | Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders |
| Q46821578 | Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease |
| Q80509480 | Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis |
| Q53373755 | An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. |
| Q31031256 | Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries |
| Q34980451 | Anti-inflammatory Effects of Flavonoids on TNBS-induced Colitis of Rats |
| Q42686834 | Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. |
| Q37856191 | Assessing response and loss of response to biological therapies in IBD. |
| Q43128291 | Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients |
| Q36165341 | Bone turnover and nutritional status in Crohn's disease: relationship to circulating mononuclear cell function and response to fish oil and antioxidants |
| Q36577698 | Brain derived neurotrophic factor inhibits apoptosis in enteric glia during gut inflammation. |
| Q43923370 | Butyrate and the cytokine-induced alpha1-proteinase inhibitor release in intestinal epithelial cells. |
| Q28143405 | Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease |
| Q37420522 | Candidate genes involved in beneficial or adverse responses to commonly eaten brassica vegetables in a New Zealand Crohn's disease cohort. |
| Q35276666 | Certolizumab pegol for the treatment of Crohn's disease |
| Q37684572 | Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease |
| Q53723979 | Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. |
| Q43602692 | Comparative outcomes of trocar puncture with sump drain, percutaneous drainage, and surgical drainage in the management of intra-abdominal abscesses in Crohn's disease |
| Q63727338 | Complement activation in plasma before and after Infliximab treatment in Crohn disease |
| Q74637041 | Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg? |
| Q37011959 | Crohn's disease: a review of current treatment with a focus on biologics. |
| Q44647507 | Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn?s disease |
| Q35190718 | Dendritic cell-epithelial cell crosstalk in the gut. |
| Q33350463 | Distribution of enteric glia and GDNF during gut inflammation |
| Q38365426 | Early investigational TNF receptor antagonists for the treatment of ulcerative colitis |
| Q92481717 | Effect of Loureirin B on Crohn's disease rat model induced by TNBS via IL-6/STAT3/NF-κB signaling pathway |
| Q44297498 | Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid-induced colitis in rats. |
| Q43804970 | Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis |
| Q80101961 | Efficacy of T2 in active Crohn's disease: a prospective study report |
| Q34604561 | Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone |
| Q45074387 | Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome |
| Q38903356 | Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). |
| Q79819563 | Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro |
| Q44563339 | Essential fatty acid status in paediatric Crohn's disease: relationship with disease activity and nutritional status. |
| Q36397893 | European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis |
| Q34336510 | Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy |
| Q51584924 | Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. |
| Q84475398 | Evaluation of anti-colitic effect of lactic acid bacteria in mice by cDNA microarray analysis |
| Q35216827 | Evaluation of new therapies for inflammatory bowel disease |
| Q57154899 | Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease |
| Q33350222 | Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle |
| Q52891216 | Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease? |
| Q53170686 | Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. |
| Q73699251 | Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease |
| Q58043146 | Histopathological parameters as predictors for the course of Crohn's disease |
| Q37578507 | How to manage difficult Crohn's disease: optimum delivery of anti-TNFs |
| Q98158903 | INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS |
| Q37310621 | Immunomodulatory and anti-inflammatory effects of chondroitin sulphate |
| Q47271726 | Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease |
| Q33541428 | Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data |
| Q78442722 | Infliximab for ulcerative colitis |
| Q59310001 | Infliximab reverses growth hormone resistance associated with inflammatory bowel disease |
| Q36177695 | Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy |
| Q40448426 | Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. |
| Q28546744 | LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease |
| Q47608070 | Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status. |
| Q41992829 | Leukocyte apheresis in the management of ulcerative colitis |
| Q34146351 | Linkage of inflammatory bowel disease to human chromosome 6p |
| Q33626027 | Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease |
| Q34949521 | Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury |
| Q35594252 | Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. |
| Q28202504 | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial |
| Q35359745 | Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper |
| Q73197599 | Mechanisms in failure of infliximab for Crohn's disease |
| Q35787649 | Mechanisms of infliximab: the reverse side of a drug effect |
| Q45242446 | Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease |
| Q36441742 | Microbial translocation across the GI tract |
| Q40524727 | Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse |
| Q40317388 | Mucosal healing of esophageal involvement of Crohn's disease with granulocyte/monocyte adsorption |
| Q40467985 | Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation. |
| Q37705033 | New pathophysiological insights and modern treatment of IBD. |
| Q34512083 | Non-invasive investigation of inflammatory bowel disease |
| Q58694450 | Novel Techniques in Endoscopy Are Useful in Evaluating Patients with Ulcerative Colitis |
| Q37616110 | Perianal fistulae in Crohn's Disease: current and future approaches to treatment. |
| Q57569257 | Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab |
| Q35760946 | Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis |
| Q42726307 | Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis |
| Q36041620 | Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? |
| Q34789021 | Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field |
| Q40266793 | Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis |
| Q43003878 | Proinflammatory cytokines increase glial fibrillary acidic protein expression in enteric glia |
| Q41378914 | Pseudomonas fluorescens alters the intestinal barrier function by modulating IL-1β expression through hematopoietic NOD2 signaling. |
| Q48711362 | Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab |
| Q33867963 | Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders. |
| Q34167771 | Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data |
| Q34609407 | Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? |
| Q33966376 | Review article: maintenance treatment of Crohn's disease |
| Q34669218 | Review article: monitoring the activity of Crohn's disease |
| Q36210314 | Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease |
| Q34406486 | Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease |
| Q44397466 | Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients |
| Q36394867 | Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health |
| Q38093778 | Statistical challenges in the evaluation of treatments for small patient populations |
| Q36175772 | Synergy between immunosuppressive therapy and enteral nutrition in the management of childhood Crohn's disease |
| Q35598172 | Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model |
| Q40421198 | Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. |
| Q45405891 | TNF-alpha, produced by feline infectious peritonitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages |
| Q43327211 | The impact of the fecal stream and stasis on immunologic reactions in ileal pouch after restorative proctocolectomy for ulcerative colitis: a prospective, pilot study. |
| Q36446929 | The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease |
| Q44535156 | The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression |
| Q37809574 | The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review |
| Q34163374 | The role of bacteria and pattern-recognition receptors in Crohn's disease. |
| Q34098863 | Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production |
| Q47349934 | Therapeutic apheresis from the early civilizations to the twenty-first century |
| Q36987442 | Therapeutic leukocytapheresis for inflammatory bowel disease |
| Q43983014 | Therapeutic response to thalidomide in Melkersson-Rosenthal syndrome: a case report |
| Q34008773 | Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs |
| Q50923712 | Treatment of Crohn's disease with certolizumab pegol. |
| Q87950405 | Treatment of inflammatory bowel disease by leukocytapheresis |
| Q24669999 | Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease |
| Q40607008 | Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells |
| Q91168567 | Two distinct colonic CD14+ subsets characterized by single-cell RNA profiling in Crohn's disease |
| Q37160876 | Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats |
| Q38833346 | Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure |
| Q36215483 | Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis. |
| Q44073510 | Whole gut lavage fluid interleukin-1beta and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remission |
| Q46562251 | cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. |
Search more.